Haematology-Oncology · Clinical trials
Chronic Myeloid Leukaemia (CML) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About chronic myeloid leukaemia (cml) — and why its trials are hard
Chronic myeloid leukaemia is a myeloproliferative neoplasm defined by the Philadelphia chromosome, the t(9;22) translocation creating the constitutively active BCR-ABL1 tyrosine kinase that drives myeloid proliferation. It classically presents in a chronic phase with leukocytosis and splenomegaly, and, if untreated, progresses through accelerated phase to fatal blast crisis. CML is the paradigm of targeted therapy: imatinib, the first BCR-ABL tyrosine kinase inhibitor, was validated in the landmark IRIS trial and converted a once-fatal disease into a chronic condition with near-normal life expectancy for many patients. Second-generation inhibitors dasatinib and nilotinib achieve faster, deeper molecular responses, while third-generation ponatinib overcomes the resistant T315I mutation. The allosteric STAMP inhibitor asciminib (ASCEMBL), which binds the myristoyl pocket rather than the ATP site, offers efficacy with improved tolerability in resistant/intolerant disease and is now moving frontline. Response is tracked by standardised BCR-ABL1 transcript levels; achieving deep molecular response can enable attempts at treatment-free remission. Adherence and TKI toxicity management are central to long-term care.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Imatinib (Gleevec) | 2001 | Frontline chronic-phase CML | IRIS | Cytogenetic/molecular response and long-term survival | Landmark trial; complete cytogenetic response in most patients with ~80-90% long-term survival, transforming prognosis |
| Dasatinib (Sprycel) | 2006 (resistant); 2010 frontline | Frontline and imatinib-resistant/intolerant CML | DASISION | Major molecular response / complete cytogenetic response | Faster, deeper responses vs imatinib (higher early MMR rates) |
| Nilotinib (Tasigna) | 2007 (resistant); 2010 frontline | Frontline and imatinib-resistant/intolerant CML | ENESTnd | Major molecular response | Superior MMR and fewer progressions to accelerated/blast phase vs imatinib |
| Ponatinib (Iclusig) | 2012 | Resistant/intolerant CML, notably T315I mutation | PACE (OPTIC for optimised dosing) | Major cytogenetic/molecular response | High response rates in T315I and multi-TKI-resistant disease; dose optimisation reduced vascular events |
| Asciminib (Scemblix) | 2021 (resistant, incl. T315I); 2024 newly diagnosed | Chronic-phase CML after two prior TKIs, T315I, and newly diagnosed | ASCEMBL (vs bosutinib); ASC4FIRST (frontline) | Major molecular response at week 24/48 | ASCEMBL MMR at week 24 ~25% vs ~13% with bosutinib; STAMP allosteric inhibitor with favourable tolerability |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in chronic myeloid leukaemia (cml) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Bosutinib (initial frontline attempt) — BELA | Missed its primary endpoint of complete cytogenetic response at 12 months versus imatinib | Early gastrointestinal toxicity and dosing/discontinuations; frontline approval later came via the reworked BFORE trial |
| Ponatinib (original frontline development) — EPIC (terminated) | The frontline programme was halted due to arterial occlusive/thrombotic vascular events | Serious cardiovascular toxicity led to a boxed warning and restriction to resistant/T315I settings rather than broad frontline use |
Choosing the right endpoint
Primary endpoints that matter in chronic myeloid leukaemia (cml) trials
- Major molecular response (MMR / MR3) — BCR-ABL1 <=0.1% on International Scale; central treatment milestone
- Complete cytogenetic response (CCyR) — No Philadelphia-positive metaphases; historically key, now often superseded by molecular measures
- Deep molecular response (MR4/MR4.5) — Prerequisite for attempting treatment-free remission
- Progression-free / event-free survival — Captures transformation to accelerated or blast phase
- Treatment-free remission (TFR) — Sustained deep response allowing TKI discontinuation without relapse
How iNGENū runs chronic myeloid leukaemia (cml) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Chronic Myeloid Leukaemia (CML) clinical trials — FAQs
Can CML be cured?
What is the T315I mutation?
Why is monitoring BCR-ABL1 transcripts important?
Ready to discuss your chronic myeloid leukaemia (cml) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal